American Academy of Family Physicians

Printer-friendly version

Share this on AAFP Connection

Share this page

IV Antibiotics, Antiemetic Recalled Because of Potential Contamination

By News Staff

The FDA is advising physicians not to use certain IV bags of the antibiotics metronidazole and ciprofloxacin and the antiemetic ondansetron because of potential mold contamination.
Product Recall
The agency said in a June 1 public health alert that it had received reports of floating matter in intravenous bags manufactured by Claris Lifesciences Ltd. in Ahmedabad, India. In a June 1 news release, Claris said that it was recalling the products as a precautionary measure.

The FDA said health care professionals should not use, and should remove from their pharmacy inventories, IV bag products manufactured by Claris and sold under the following labels:
  • Claris (metronidazole, ciprofloxacin, ondansetron);
  • Pfizer Inc. (metronidazole, ciprofloxacin, ondansetron);
  • Sagent Pharmaceuticals Inc. (metronidazole, ondansetron); and
  • West-Ward Pharmaceutical Corp. (metronidazole, ondansetron).
Ciprofloxacin IV bags distributed by Sagent are not manufactured by Claris and are not subject to the recall, according to the FDA.

The agency said microbiological analysis of white matter in a bag of metronidazole identified the substance as a Cladosporium mold, which can cause infections in susceptible patients, including immunocompromised individuals.

Sagent said in a June 2 news release that such infections can be fatal. However, the FDA said it is not aware of any reports of injuries linked to administration of the recalled products.

White matter in a bag of ondansetron -- which is used to treat nausea and vomiting associated with chemotherapy or surgery -- also is being analyzed, said agency officials.

Patients who have received the recalled products should be observed for signs or symptoms of illness and treated appropriately.

Claris said questions about returning unused product should be directed to the company at (877) 725- 2747. Health care workers with medical questions about the products may call the same number and ask for medical affairs, the company said.

Adverse events associated with the use of recalled products should be reported to the FDA's MedWatch program.

Share this on AAFP Connection

Health of the Public

Study: PPI Does Not Routinely Improve Asthma Control

Recalled Oral Contraceptives Pose Pregnancy Risk

CDC to Fund 2D Vaccine Barcoding Pilot

2012 Immunization Schedules Reflect Multiple Changes

Study: Cognitive Decline Detected in Middle-aged Adults

CDC Toolkit Can Help Clinicians Fight Norovirus Infection

Patient-Centered Care Linked to Lower Mortality

Study: Inappropriate Cancer Screenings Continue

Novartis Manufacturing Plant Closes After Drug Mix-ups

FDA Announces Classwide REMS for TIRF Medications

New Infants' Acetaminophen Products Hit Store Shelves

Avoid Environmental Factors Linked to Breast Cancer

Risk for Thrombosis Prompts REMS for Rivaroxaban

Common Drugs Implicated in Most Emergency Hospitalizations

CDC Launches Campaign for Child Medication Safety

HHS Blocks Expanded OTC Access to Plan B

Push Is On to Vaccinate Pregnant, Postpartum Women

FDA Committee Votes to Broaden PCV13 Indication

AAFP Foundation Program Aims to Fight Chronic Disease

NIAAA Alcohol Screening Guide Targets Teens

Walgreens, AAFP Launch Flu Vaccine Pilot in Five States

Helping Patients Quit Smoking Starts With a Question

Trilipix Efficacy in Question, Says FDA

USPSTF Addresses Skin Cancer, Obesity, Cervical Cancer Screening

AAFP Endorses ACP Guideline on ED

ACIP Recommends Expanded HPV, Hepatitis B Vaccination

Bacterial Contamination Spurs Nasal Spray Recall

CDC Renews Call for PCV13 Vaccination

USPSTF Recommends Against PSA Screening

AAFP Supports HHS' Million Hearts Initiative

FDA Phases Out Primatene Mist Inhalers

AHRQ Guides Explain Benefits, Risks of GERD Treatments

Tar Wars Winner Gives Back

Office Champions Project Nets Smoking Cessation Gains

Multiple Lots of Oral Contraceptives Recalled

New Vaccine Review Finds Few Adverse Events

HPV Vaccination Rates Still Lag, Says CDC

Renal Injury Prompts Reclast Label Changes

High-dose Citalopram Linked to Abnormal Heart Rhythms

AHRQ Sleep Apnea Guides Review Diagnosis, Management

Board Chair Spotlights Breadth of Family Medicine Training

USPSTF Softens Stance on Bladder Cancer Screening

HHS Expands Coverage for Women's Preventive Services

Teledermatology Project Aids Underserved Patients

New Chantix Warnings Cite Cardiovascular Risk

Pertussis Outbreaks Lead to CDC Alert on PCR Testing